1 results
Advancing Treatment Options for Recurrent Glioblastoma
Adults with recurrent glioblastoma may be eligible for an NIH research study evaluating LMP744, an investigational drug with FDA orphan drug designation for gliomas. The study aims to assess the drug's safety and both its short- and long-term treatment effects.